Skip to main content
SanofiRevenue

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

Source: Autobound Signal API · 81 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi reported that its drug Dupixent, developed with Regeneron, generated sales of €9.3 billion in the first half of 2026, a 28.6% increase year-over-year.

Source

Article excerpt

Sanofi SNY and Regeneron Pharmaceuticals REGN announced that they have expanded their existing longstanding antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation. Per the expanded agreement, the companies will co-develop and co-commercialize four Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα). One of the programs, REGN20423, is a long-acting IL-13 monoclonal antibody currently being evaluated in a phase I study for atopic dermatitis. The other three antibodies are expected to enter clinical studies in 2027. Regeneron will also have an option to include Sanofi's investigational candidate, lunsekimig, a bispecific nanobody therapy targeting TSLP and IL-13, in the latest collaboration after completion of its phase III studies in chronic obstructive pulmonary disease. REGN is entitled to receive an upfront payment of $1 billion from SNY. It is also eligible to receive up to $7 billion in additional development, regulatory and commercial milestone payments. Both companies will equally share development and commercialization costs and future profits from the potential products globally. Regeneron will lead research and development activities, while Sanofi will oversee global commercial efforts. Sanofi and Regeneron also...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted from this sentence

Dupixent generated sales of €9.3 billion in the first half of 2026, up 28.6% year over year.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

The full record

From the Signal API record

Topics and mentions

Product tags

  • general technology
  • medical

Extraction

Confidence
90%
Detected
Oct 2, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/41aa26e4-eba2-5095-0eab-2bcb9dfae664 returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "41aa26e4-eba2-5095-0eab-2bcb9dfae664",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-10-02T12:45:00+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://uk.finance.yahoo.com/news/sanofi-regeneron-expand-immunology-alliance-124500667.html",
    "title": "Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Yahoo Finance UK",
    "excerpt": "Sanofi SNY and Regeneron Pharmaceuticals REGN announced that they have expanded their existing longstanding antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation. Per the expanded agreement, the companies will co-develop and co-commercialize four Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα). One of the programs, REGN20423, is a long-acting IL-13 monoclonal antibody currently being evaluated in a phase I study for atopic dermatitis. The other three antibodies are expected to enter clinical studies in 2027. Regeneron will also have an option to include Sanofi's investigational candidate, lunsekimig, a bispecific nanobody therapy targeting TSLP and IL-13, in the latest collaboration after completion of its phase III studies in chronic obstructive pulmonary disease. REGN is entitled to receive an upfront payment of $1 billion from SNY. It is also eligible to receive up to $7 billion in additional development, regulatory and commercial milestone payments. Both companies will equally share development and commercialization costs and future profits from the potential products globally. Regeneron will lead research and development activities, while Sanofi will oversee global commercial efforts. Sanofi and Regeneron also agreed...",
    "product": "Dupixent",
    "summary": "Sanofi reported that its drug Dupixent, developed with Regeneron, generated sales of €9.3 billion in the first half of 2026, a 28.6% increase year-over-year.",
    "planning": false,
    "image_url": "https://s.yimg.com/lo/mysterio/api/43ec44a0fcaeceb560cd1f361192a079912c78a948ae90b4a1c8f5efdfa2d60c/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2F4c89fa4c828d913dc49739912177a966.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "Dupixent",
      "full_text": "Dupixent",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-02T12:45:00Z",
    "article_sentence": "Dupixent generated sales of €9.3 billion in the first half of 2026, up 28.6% year over year.",
    "related_company_name": "Regeneron Pharmaceuticals",
    "related_company_domain": "regeneron.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.